Ningbo Menovo Pharmaceutical's subsidiary has obtained the registration certificate for Irbesartan Hydrochlorothiazide Tablets.
Meinuohua (603538.SH) released an announcement that its wholly-owned subsidiary Ningbo Meinuohua Tiankang Pharmaceutical Co., Ltd. (abbreviated...
Ningbo Menovo Pharmaceutical (603538.SH) announced that its wholly-owned subsidiary, Ningbo Menovo Pharmaceutical Tiankang Pharmaceutical Co., Ltd. ("Ningbo Menovo Pharmaceutical Tiankang"), recently received the "Drug Registration Certificate" issued by the National Medical Products Administration.
Indication: Used for the treatment of primary hypertension. The compound contains the angiotensin II receptor antagonist eprosartan and the thiazide diuretic hydrochlorothiazide. The combination of hydrochlorothiazide and eprosartan within its recommended therapeutic dose range can produce a synergistic antihypertensive effect.
Related Articles
INFINITY DEV(00640): Stock merger has taken effect
CIRC(01763): Each hand of "24 same-spoke K1" will distribute a dividend of 22.5 yuan on October 27th.
XD INC (02400) issues 143,700 stock options.
INFINITY DEV(00640): Stock merger has taken effect
CIRC(01763): Each hand of "24 same-spoke K1" will distribute a dividend of 22.5 yuan on October 27th.
XD INC (02400) issues 143,700 stock options.
RECOMMEND
Why European Automakers Are Opposing Dutch Sanctions
20/10/2025
Domestic Commercial Rockets Enter Batch Launch Era: Behind the Scenes a Sixfold Cost Gap and Reusability as the Key Breakthrough
20/10/2025
Multiple Positive Catalysts Lift Tech Stocks; UBS Elevates China Tech to Most Attractive, Citing AI as Core Rationale
20/10/2025
